Parnell Pharmaceuticals Holdings EBITDA Margin 2014-2018 | PARNF
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Parnell Pharmaceuticals Holdings (PARNF) over the last 10 years. The current EBITDA margin for Parnell Pharmaceuticals Holdings as of June 30, 2018 is .
| Parnell Pharmaceuticals Holdings EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2018-03-31 |
$0.01B |
$0.01B |
66.67% |
| 2016-12-31 |
$0.01B |
$0.01B |
100.00% |
| 2016-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2015-12-31 |
$0.01B |
$0.01B |
100.00% |
| 2015-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2015-06-30 |
$0.01B |
$0.01B |
100.00% |
| 2014-12-31 |
$0.00B |
$0.00B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
